This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry June 10, 2025 By Christopher Cole News Article The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond. Kennedy Jr.
CMS is issuing unique J-codes for 505(b)(2) drugs, classifying them as sole-source products if not therapeutically equivalent. This pathway reduces submission denial risk, accelerates drugdevelopment, and offers potential market exclusivity for up to 7 years.
Nanoparticles have attracted particular attention, including those based on lipids, polymers (natural and synthetic), lipid-polymer hybrids, dendrimers, inorganic materials (metals, magnetic compounds, carbon nanotubes, silica-based systems, etc.).
SHOW MORE With robust pipelines, cell therapy remains the major driver for drugdevelopment. Development Trends: Oncology at the Forefront Gene therapy currently ranks third among therapeutic focus areas, with 2151 compounds in development in 2024 ( Figure ).
Growth of ADC manufacturing According to the press release, the ADC pipeline has been growing in recent years, driven by early successes against diseases such as human epidermal growth factor receptor 2 (HER2)-positive breast cancer; currently, 70% of these drugs are manufactured by CDMOs (1). Patients can’t wait.
link] Recent Videos Related Content Looking Beyond mRNA-based COVID-19 Vaccines to Innovative Therapeutics Cheryl Barton June 24th 2025 Article mRNA technologies offer great promise in immunotherapy and non-immunogenic applications. Pharmaceutical Compounding Calculations, Part Two–Bulk Drugs Paul L. link] Haigney, S.
cancer and vaccines), and non-immunogenic applications (e.g., cancer and vaccines), and non-immunogenic applications (e.g., Several types of mRNA-based vaccines have emerged, namely non-replicating linear mRNAs (NRM), self-amplifying mRNAs (saRNAs), and circular mRNAs (circRNAs). Types of messenger RNA (mRNA)-based vaccines.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines Feliza Mirasol April 30th 2024 Podcast In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Compounded GLP-1RAs have completely disrupted pricing frameworks for Wegovy and Mounjaro, what happens now? Robert Barrie June 27, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The list price for a month’s supply of 2.4mg Wegovy – the drug’s highest does – is $1,350 in the US, whereas the same dose in the UK costs £175.80
In March 2025, Novo Nordisk discounted the cost of all doses to $499 per month to competitively price its prized asset against cheaper compounded alternatives. Compounded semaglutide is a personalised weight loss medicine, which is chemically identical to branded alternatives.
Sharing knowledge, exploring investments Key Takeaways Abu Dhabi signed MoUs with BI, Sanofi, and Abbott to expand vaccine R&D, local pharma production, and digital health capabilities. BI’s OpnME platform access aims to enhance Abu Dhabi’s clinical research by providing compounds, networks, and collaboration tools. Press Release.
Thakar Varanya Chaiyaperm View All News Article Bulk drug calculations for different types of active moieties and drugs require different calculations and labeling. Calculations provide the amount of drug specified in the medication order needed for compounding; it is the objective of the medication order.
In the marathon of drugdevelopment, where billions of dollars and over a decade of research are the norm, drug repurposing is quietly reshaping the landscape. Evolving regulatory frameworks: One of the biggest hurdles is navigating the complex regulatory landscape that governs clinical drugdevelopment.
million in 2023, with a predicted compound annual growth rate (CAGR) of 4.1 Demand for cell lines “in drugdevelopment , vaccine production, and therapeutic research is surging”, setting the market up for significant expansion, Ghosh noted. Total cell line product sales are expected to reach $3,124.4
As drugdevelopers consider oligos potential, they often explore innovations in chemical modifications and delivery systems to ensure these therapies reach their full potential. Finally, oligo metabolites often share similar structures and molecular weights with parent compounds, leading to potential interference during analysis.
17 Accelerating drugdevelopment The first issue of 2023 , 18 dealt with accelerating drugdevelopment. Repurposing of currently marketed products, eg, methotrexate, 20 was an important and effective strategy in combatting COVID-19, particularly in the early stages prior to effective vaccines being developed.
The article focuses on challenges faced in drugdevelopment, government incentive programs, grants, and various therapies used to diagnose or treat rare diseases. How challenging is the drugdevelopment plan Drugdevelopment plans for rare diseases can be circuitous, resulting in fewer participation from companies.
India has traced a journey of grit and glory to emerge as a major supplier of generic drugs and vaccines globally. IBER Report 2023 divulges, “The biopharma vaccines (non-COVID alone) market makes a significant daily contribution of approximately $38 million. Today, it is a key player in the global pharma landscape.
Despite the enormous growth being enjoyed by the global oncology market, potential cancer cures are left on laboratory shelves on a regular basis, according to Dr Victoria John, head of clinical partnerships at Cancer Research UK’s DrugDevelopment Office. “You can get vaccines now to prevent cervical cancer.
True enough, the use of liposomes and LNPs as carriers for highly specialised drug and biologic payloads, notably mRNA therapies, has experienced remarkable growth—notably, the initial SARS-CoV-2 vaccines authorised for use employed LNPs as delivery mechanisms for mRNA payloads. So, in that sense, both are effective in drug delivery.
In the time since, it has built a pipeline that includes eight clinical-stage compounds, including two licensed by AstraZeneca and Merck & Co. Once the deal is complete, LaNova will become a wholly owned subsidiary of Sino Biopharm , which previously invested in LaNova’s Series C1 financing that was announced last October. and Europe.
MALDI-TOF works on the basis of the ionisation of chemical compounds and measurements of their mass to charge (m/z) ratio. The safety and efficacy of mRNA vaccines should be a game changer and is the likely solution to antibiotic-resistant microorganisms and emerging viral pathogens.”
Several drugdevelopment trends are driving injectables demand. This includes the rising number of biologic drugs on the market, which are mostly administered parenterally. During the Covid-19 pandemic, large-scale vaccine production placed unprecedented demand on the parenteral packaging industry.
Regulatory pressures, lengthy drugdevelopment times, and the fact that drug prices have become politicised have raised risks and cut revenue projections, leading to the biotech sector falling out of fashion. Moreover, the range of companies benefiting from investor interest has not been limited to those developing a vaccine.
While BioNTech is best known for co-developing the first approved mRNA vaccine with Pfizer, the company continues to invest heavily in mRNA research targeting various solid tumors and infectious diseases. billion (1). billion (1). Implications of RFK Jr.’s
Research and development highlights from the research period include the company’s work with Mirati Therapeutics in developing methods to determine torsion rotational energy barriers of the clinical compound, MRTX1719, which is being developed for use as an inhibiter to MTAP-deleted cancers.
According to a survey, a majority from a cohort of pharmaceutical leaders expressed that the drugdevelopment plans, which ideally takes years of research, when asked to prepare in haste, may cause serious implications on the health of the population. However, these VLPs do not contain genetic material, making them non-infectious.
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail Felicity Thomas May 28th 2024 Podcast In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space. Implications of RFK Jr.’s Implications of RFK Jr.’s
Linking Neuroscience to Therapeutic Development Key Takeaways ·European biotech startup Elkedonia secures €11.25M (US$12.9M) in seed funding, integrating Sorbonne University research with Argobio’s drugdevelopment expertise.
These biopharmaceuticals encompass a range of products including vaccines, recombinant therapeutic proteins, tissues, cells and gene therapies – all sourced from living organisms. 1 However, the entry of biologics into the pharmaceutical market is not without unique challenges, particularly when compared to small molecule drugs.
Novel therapeutics and vaccines for malaria. In September, researchers from Oxford University shared their findings from a Phase IIb study with a more efficacious malaria vaccine called R21, which met the WHO’s 75% efficacy threshold. Both vaccines are based on recombinant proteins and attack the parasite during the sporozoite stage.
When COVID hit, the urgent need to accelerate drugdevelopment meant shrinking timelines from years to months, with no room for compromises on quality. The rest is history: vaccines were delivered worldwide in record time, saving millions of lives. Cloud computing was one of the facilitators of this shift.
of the newly combined company The combined companies’ focus is to advance Elicio’s lymph node-targeting amphiphile technology to develop immunotherapies & also focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors is currently being evaluated in the P-I trial (AMPLIFY-201) for PDAC and CRC.
However, with this kind of promise comes more scientific, ethical and financial questions that healthcare providers and drugdevelopment professionals must seriously consider. As more people take them and their uses grow, so does their potential.
Why have drugs to treat the liver disease MASH reached a tipping point? How did Hims & Hers convince Childish Gambino to license his song “This is America” for a Super Bowl ad about compounded GLP-1 drugs? ’s confirmation hearings, including some contentious questions about vaccines and autism from Sens.
4) Why is there a need for new drugs to combat the continuously mutating virus, despite the effectiveness of vaccines? With some diseases like smallpox and polio, vaccines have an extremely high likelihood of preventing a person from getting the disease and stopping community transmission.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content